2025
Cardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor–Related Myocarditis
Hammer M, Tysarowski M, Fuss C, Bader A. Cardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor–Related Myocarditis. Echocardiography 2025, 42: e70131. PMID: 40067334, DOI: 10.1111/echo.70131.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsImmune checkpoint inhibitorsCardiac magnetic resonance imagingMagnetic resonance imagingAssociated with immune-related adverse eventsCardiac immune-related adverse eventsMechanisms of immune checkpoint inhibitorsICI-associated myocarditisICI-related myocarditisResonance imagingPersonalized cancer immunotherapySevere cardiovascular complicationsImmune tolerance pathwayCheckpoint inhibitorsCancer immunotherapyCardiac complicationsCombination therapyTumor cytotoxicityClinical presentationCardiovascular complicationsAdverse eventsTherapeutic efficacyOncological treatmentTherapeutic strategiesMyocarditis
2024
Does cancer clinical trial enrollment for sexual and gender minority people differ from heterosexual, cisgender people?
Alpert A, Obedin-Maliver J, Gjelsvik A, Amanullah S, Shireman T, Blosnich J. Does cancer clinical trial enrollment for sexual and gender minority people differ from heterosexual, cisgender people? Contemporary Clinical Trials 2024, 146: 107695. PMID: 39303766, DOI: 10.1016/j.cct.2024.107695.Peer-Reviewed Original ResearchBehavioral Risk Factor Surveillance SurveyCancer clinical trial enrollmentClinical trial enrollmentTrial enrollmentRisk Factor Surveillance SurveySGM peopleNon-SGM individualsClinical trial participationCancer disparitiesSurveillance SurveyReport participationGender minority peopleTrial participantsSGM statusSGM individualsPartnership statusLogistic regressionCisgender peopleData collection methodsEnrollmentOncological treatmentOddsMinority peopleParticipantsSGMAdjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
Sutton T, Billingsley K, Johnson A, Corless C, Blanke C, Heinrich M, Mayo S. Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable? Journal Of Surgical Oncology 2024, 130: 40-46. PMID: 38924626, DOI: 10.1002/jso.27654.Peer-Reviewed Original ResearchHigh-risk gastrointestinal stromal tumorsRecurrence-free survivalGastrointestinal stromal tumorsResected gastrointestinal stromal tumorsAdjuvant imatinibOverall survivalStromal tumorsAdjuvant therapyDuration of adjuvant imatinibBenefit of adjuvant therapyMonths of postsurgical follow-upMultivariate Cox proportional hazards modelPostsurgical follow-upKaplan-Meier analysisCox proportional hazards modelsProportional hazards modelRadiographic recurrenceImatinib resistanceReviewed patientsFollow-upImatinibOncological treatmentCytocidal effectCancer CenterPatientsPrevalence and Predicting Factors of Pretreatment Dysphagia in Veterans With Head and Neck Cancer: A Pilot Study
Warner H, Romanelli L, Adams K, Xiao J, Young N. Prevalence and Predicting Factors of Pretreatment Dysphagia in Veterans With Head and Neck Cancer: A Pilot Study. Perspectives Of The ASHA Special Interest Groups 2024, 9: 427-439. DOI: 10.1044/2023_persp-22-00171.Peer-Reviewed Original ResearchHead and neck cancerDiagnosis of head and neck cancerStage of cancer diagnosisNeck cancerStatistically significant relationshipMedical record reviewPilot studyRetrospective medical record reviewReferral approachRecord reviewTargeted interventionsDysphagia assessmentPredictive factorsSignificant relationshipCancer diagnosisPercutaneous endoscopic gastrostomy placementClinically significant implicationsVeteransPosttreatment dysphagiaPrevalenceOncological treatmentPatient populationPretreatment dysphagiaInitiation of oncological treatmentWest-Haven
2017
Palliative Oncologic Care Curricula for Providers in Resource-Limited and Underserved Communities: a Systematic Review
Xu M, Su D, Deboer R, Garcia M, Tahir P, Anderson W, Kinderman A, Braunstein S, Sherertz T. Palliative Oncologic Care Curricula for Providers in Resource-Limited and Underserved Communities: a Systematic Review. Journal Of Cancer Education 2017, 34: 205-215. PMID: 29264703, DOI: 10.1007/s13187-017-1310-8.Peer-Reviewed Original ResearchConceptsPalliative oncological treatmentSupportive cancer carePalliative careCancer careCare curriculumResource-limited settingsPalliative care education programPrinciples of palliative carePalliative care curriculumAmerican Indian/Alaskan Native communitiesCare education programOncological treatmentProspective cohort studyResource-limited communitiesCancer patientsCumulative IndexSymptom managementWeb of ScienceParticipant satisfactionGrey literatureCareCohort studyOutcome reportingSystematic reviewEducation programs
2016
Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop
Smith G, Ganz P, Bekelman J, Chmura S, Dignam J, Efstathiou J, Jagsi R, Johnstone P, Steinberg M, Williams S, Yu J, Zietman A, Weichselbaum R, Shih Y. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. International Journal Of Radiation Oncology • Biology • Physics 2016, 97: 450-461. PMID: 28011046, PMCID: PMC6044722, DOI: 10.1016/j.ijrobp.2016.10.042.Peer-Reviewed Original ResearchMeSH KeywordsCosts and Cost AnalysisDecision MakingDiffusion of InnovationHumansNational Academies of Science, Engineering, and Medicine, U.S., Health and Medicine DivisionNeoplasmsProgram EvaluationProton TherapyRadiation OncologyRadiotherapyRadiotherapy, Intensity-ModulatedResearch PersonnelTechnology, RadiologicUnited StatesConceptsRadiation oncology communityRadiation oncology treatmentsRadiation oncologyAdvanced radiation technologiesOncology communityOncological treatmentNational Cancer Policy Forum of the National Academies of SciencesNational Cancer Policy ForumPractice of radiation oncologyRadiation oncology practiceProspective registry dataCancer care decisionsGeneration of scientific evidenceRadiation therapyScientific evidenceEvidence-based effortsComparative effectiveness dataCancer careClinical effectsCare decisionsQuality benchmark dataDe-adoptionRegistry dataThe National Academy of SciencesOncology practice
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply